Caredx leads transplant innovation with aikidney, an ai clinical decision support tool for predicting allograft rejection risk

South san francisco, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it plans to expand its growing multimodality portfolio with aikidney™, a new allograft risk assessment clinical decision support tool, in development, that includes allosure® and other transplant metrics. this foll
CDNA Ratings Summary
CDNA Quant Ranking